Le Lézard
Classified in: Health
Subjects: NPT, FDA, AVO, MAT

Power to Decide Statement on Over-the-Counter Birth Control Release and Pricing


First ever FDA-approved over-the-counter birth control, Opill, set to hit store shelves soon.

WASHINGTON, March 4, 2024 /PRNewswire-PRWeb/ -- Today, the pharmaceutical company Perrigo announced that it will begin shipping the first ever FDA-approved over-the-counter (OTC) daily oral contraceptive pill, Opill, to retailers across the country. This marks a historic advancement in access to contraception, which for decades advocates have been fighting for.

"At a time when reproductive health and rights are under attack, it is critical that everyone has the ability to access a birth control pill without barriers such as cost, prescriptions, insurance coverage and medical appointments," said Power to Decide, CEO, Dr. Raegan McDonald-Mosley, MD, MPH.

Additionally, Perrigo recommended a retail price of $19.99 for a one-month supply of Opill, and $49.99 for a three-month supply. However, it will be up to individual retailers to set their price, which may vary across stores and locations. Consumers can expect to find Opill in retailers and pharmacies in the coming weeks.

While the OTC birth control pill will greatly increase contraceptive access, the price will continue to be a barrier for many. There is still a need for insurance coverage of all OTC contraception without a prescription, a robust consumer assistance program from Perrigo, and availability of the full range of contraceptive methods - including Opill - at safety net clinics to ensure equitable access of contraception for all.

In response to Perrigo's announcement, Power to Decide CEO, Dr. Raegan McDonald-Mosley, MD, MPH, issued the following statement:

"FDA approval of the first over-the-counter birth control pill is a major milestone in reproductive health and a critical step toward ensuring contraceptive access for all, but we need to make sure that those in need can actually afford to use it. When it comes to contraception, affordability is critical to meaningful access.

"As a practicing OBGYN, I know that most patients do not need to visit their health care provider to safely and effectively use birth control pills, and that the requirement for a visit presents significant obstacles for many people. Ensuring that over-the-counter birth control is affordable, covered by insurance and accessible for all ages will especially help those in contraceptive deserts?counties where people in need of publicly funded contraceptive care lack reasonable access to a clinic that provides the full range of contraceptive methods.

"At a time when reproductive health and rights are under attack, it is critical that everyone has the ability to access a birth control pill without barriers such as cost, prescriptions, insurance coverage and medical appointments. Heading to your local convenience or retail store for OTC birth control and not having to wait weeks or even months for a medical appointment is a game changer. At Power to Decide, we will continue to push for everyone to have equitable access to take control of their reproductive and sexual health care."

To explore all your birth control options and learn more about Opill, visit Bedsider.org.

Power to Decide is a nonprofit, nonpartisan organization that works to advance sexual and reproductive well-being for all by providing trusted information, expanding access to quality services, and catalyzing culture change.

Bedsider, a program of Power to Decide, is an evidence-based digital platform that offers medically-accurate, relevant, and resonate information on all aspects of reproductive well-being, including sex, sexual health, and birth control. Find a birth control method that works for you at Bedsider.org.

Media Contact

Jacqueline Pelella, Power to Decide, 202-478-8534, [email protected], https://powertodecide.org/

SOURCE Power to Decide


These press releases may also interest you

at 04:19
Medivir AB (STO: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that an abstract for the combination of fostroxacitabine bralpamide (fostrox) + Lenvima® in...

at 04:15
Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced the expansion of its LV Edge System with the launch of a fully stable cell line development service. There are now two ways for customers to...

at 04:07
Huma Therapeutics ("Huma"), a leader in global digital health innovation, together with Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the launch of their innovative bladder cancer treatment companion app in...

at 04:00
Calibre Scientific is pleased to announce the acquisition of Camlab Limited ("Camlab" or the "Company"), a UK-based supplier of scientific equipment, chemicals, consumables, labware, and other laboratory supplies and services to customers in the...

at 04:00
Hurom, a pioneer in the development of the slow juicer and a leader in the global market, is stepping up efforts to safeguard patent rights worldwide to protect its proprietary technology and contribute to a healthy industry ecosystem. Despite...

at 03:46
Allied Market Research published a report titled, "Biosimilar Testing and Development Services Market Share, Size, Competitive Landscape and Trend Analysis Report by Type, by End User: Global Opportunity Analysis and...



News published on and distributed by: